ABU DHABI, United Arab Emirates — Whether a newer class of drugs, the sodium glucose cotransporter 2 (SGLT2) inhibitors, should now be considered as first-line therapy in patients with type 2 diabetes ...

In a real-world study of patients aged 60 years or older with diabetes, SGLT2 inhibitor users experienced a significantly slower decline in estimated glomerular filtration rate compared with DPP4 ...

Patients with T2D who received GLP-1RAs or SGLT2 inhibitors were not associated with an increased risk for ARDs compared with DPP4 inhibitors.

Please provide your email address to receive an email when new articles are posted on . Treatment with sodium-glucose cotransporter-2 inhibitors for type 2 diabetes may reduce the risk for rheumatoid ...

Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors demonstrated a nearly 50% lower risk for systemic autoimmune rheumatic disease vs. those who received dipeptidyl ...

New data from the landmark FLOW trial, which linked the glucagon peptide 1 (GLP-1) receptor agonist semaglutide with significant kidney outcomes in patients with type 2 diabetes (T2D) and chronic ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

New findings add to the pile of research on the possible neuroprotective effects of drugs like dapagliflozin, empagliflozin, and dulaglutide for patients with type 2 diabetes. The primary outcome was ...

Credit: Getty Images Researchers compared rates of gout medication initiation among patients with gout and type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists. The use of ...

Estimated risk difference varied from −2.45 to 0.63 percentage points with SGLT2 vs dulaglutide among older adults. HealthDay News — For older adults with type 2 diabetes, the risk for dementia seems ...

SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis. After adjustments, patients on SGLT2 inhibitors had a significantly reduced risk of progression to severe ...

A recent study published in the Journal of the American Medical Association revealed that the use of sodium-glucose ...